Skip to content

Total Current Assets at other companies

Eli Lilly logo
Eli LillyLLY
$54.84B+32.9%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$395.25M+12.3%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$316.11M-12.9%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$589.04M+156%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$480.24M+18.4%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$677.43M+35.2%

Other financials

Income statement

See full
Operating income-$70.0M-47.5%
Net income-$69.7M-74.5%
EPS (diluted)-$0.98-55.6%

Balance sheet

See full
Cash & equivalents$298.5M+9.9%
Total debt$100.8M+33.3%
Total equity$254.0M-37.7%
Total assets$400.4M-21.7%

Cash flow

See full
Operating cash flow-$66.3M-73.8%
CapEx--100%
Free cash flow-$66.3M-73.6%

Valuation

See full
Market cap$1.56B-45.9%
Enterprise value$1.36B-50.0%

Returns & leverage

See full
Return on equity-77.7%-221pp
Debt / equity0.4×+0.2×
Current ratio8.6×-12.5×

Where this comes from

Reported directly by MoonLake Immunotherapeutics in its filing.

Tagged under the XBRL concept us-gaap:AssetsCurrent.

The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about MoonLake Immunotherapeutics's total current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MoonLake Immunotherapeutics's total current assets?
MoonLake Immunotherapeutics (MLTX) reported total current assets of $396.64M in Q1 2026.
How has MoonLake Immunotherapeutics's total current assets changed year-over-year?
MoonLake Immunotherapeutics's total current assets decreased by 21.7% year-over-year, from $506.26M to $396.64M.
What is the long-term trend for MoonLake Immunotherapeutics's total current assets?
Over 5 years (2020 to 2025), MoonLake Immunotherapeutics's total current assets has grown at a 204.2% compound annual growth rate (CAGR), from $1.62M to $421.69M.
What does total current assets mean?
The sum of all assets expected to be converted to cash or consumed within one year — cash, receivables, inventory, and prepaid expenses.